ClinicalTrials.gg
CompletedNCT03123250WATERIIUpdated Jun 28, 2023Results posted

Waterjet Ablation Therapy for Endoscopic Resection of Prostate Tissue II

An interventional study of Aquablation in Benign Prostatic Hyperplasia (BPH), sponsored by PROCEPT BioRobotics. Completed at 16 sites in 2 countries. Open to male participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2023-06-28.

Sponsored by PROCEPT BioRobotics · Not applicable, Interventional, and Treatment

How we know

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
101
Allocation
Not applicable
Ages
45 Years to 80 Years
Sex
Male
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 188 studies in Prostatic Hyperplasia with a site in United States — 29 open to participants now, 48 under way, none of them phase 3. Prostatic Hyperplasia · United States.

Enrollment
68th of 150
101 · median 83
Started
2017
with 5 others
No phase
63 of 188
13 open now
Registered
107th of 188
by date

Among the 188 studies in Prostatic Hyperplasia with a site in United States, this one is the 68th largest by enrollment of the 150 interventional ones that give a count, is one of 6 that started in 2017, is one of 63 with no phase, and was the 107th registered.

Prostatic Hyperplasia

831 studies on the registry are indexed under Prostatic Hyperplasia; 180 are open to participants now.

Browse Prostatic Hyperplasia studies →

Open to participants now

29 of the 188 studies in Prostatic Hyperplasia with a site in United States are open now. Recruiting first, the newest first:

24 more — sign in →

All 29 open studies →

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 103 Prostatic Hyperplasia studies recruiting now, 70 (68%) set no upper age limit and 4 (4%) stop at 75 or younger; 7 take children under 18; 7 take healthy volunteers.

This study: 45 Years to 80 Years · male · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 188 studies in Prostatic Hyperplasia with a site in United States, or all of them as a file.
02

Study summary

Single-arm, interventional pivotal clinical trial collecting patient data from use of the AQUABEAM System, a personalized image-guided waterjet resection system that utilizes a high-velocity saline stream to resect and remove prostate tissue in males suffering from Lower Urinary Tract Symptoms (LUTS) due to Benign Prostatic Hyperplasia (BPH) with prostate volumes between 80 mL and 150 mL. The primary endpoints for safety and effectiveness will be measured at 3 months post-treatment. Treated subjects will be followed out to 60 months to collect long-term clinical data.

03

Conditions studied

  • Benign Prostatic Hyperplasia (BPH)

Keywords

  • Lower Urinary Tract Symptoms (LUTS)
  • AQUABEAM
  • Aquablation
  • Benign Prostatic Hyperplasia (BPH)
04

Who can participate

Ages eligible
45 Years to 80 Years
Sexes eligible
Male
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Male age 45-80 years.
  • Subject has diagnosis of lower urinary tract symptoms due to benign prostatic enlargement causing bladder outlet obstruction.
  • Subject has an IPSS score greater than or equal to 12.
  • Maximum urinary flow rate (Qmax) less than 15mL/s.
  • Serum creatinine \< 2 mg/dL within 30 days of surgery.
  • History of inadequate or failed response, , or refusal to medical therapy.
  • Prostate size ≥ 80 mL and ≤ 150 mL as measured by TRUS.
  • Patient is mentally capable and willing to sign a study-specific form.

Exclusion criteria

Exclusion Criteria:

  • ≥ 42.
  • Patients unable to stop anticoagulants, antiplatelet agents, or non-steroidal anti-inflammatory agents (NSAIDs, including aspirin greater or equal to 100mg) prior to treatment per standard of care.
  • Participants using systemic immune-suppressants including (except inhalants); unable to withhold non-steroidal anti-inflammatory agents (NSAIDs, including aspirin) prior to treatment per standard or care except for low dose aspirin (e.g. less than or equal to 100mg).
  • to both general and spinal anesthesia.
  • Any severe illness that would prevent complete study participation or confound study results.
  • History of prostate cancer or current/suspected bladder cancer. Prostate cancer should be ruled out before participation to the satisfaction of the investigator if PSA is above acceptable thresholds.
  • History of actively treated bladder cancer within the past two (2) years.
  • bladder calculus or bladder diverticulum (e.g., pouch size >20% of full bladder size).
  • Active infection, including urinary tract infection or prostatitis.
  • Urinary catheter use daily for 90 or more days consecutively.
  • Previous urinary tract surgery such as e.g. urinary diversion, artificial urinary sphincter or penile prosthesis.
  • Ever been diagnosed with a clinically significant urethral stricture or meatal stenosis, or bladder neck contracture.
  • Known damage to external urinary sphincter.
  • Has had an open heart surgery, or cardiac arrest \< 180 days prior to the date of .
  • Participants using anticholinergics specifically for bladder problems. Use of medications with anticholinergic properties is allowable provided the patient does not have documented adverse urinary side effects from these medications.
  • Subject is unwilling to accept a transfusion should one be required.
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Corticosteroids (steroids)

Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.

Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
101 participants (actual)

Study arms

  • Experimental
    Aquablation procedure

    Device: Aquablation

Interventions

  • DeviceAquablation

    The procedure is performed with the AquaBeam System. It is designed to utilize a high-velocity sterile saline waterjet as the cutting medium, which is projected through a nozzle positioned within the prostatic urethra. The Aquablation procedure integrates real-time ultrasound imaging with a robotically executed surgeon guided high-velocity waterjet to resect prostate tissue.

06

What researchers measure

Primary outcomes

  1. Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment

    The percentage of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment.

    Time frame: 3 months post-treatment

  2. Change in Total International Prostate Symptom Score (IPSS) Score at 3 Months as Compared to Baseline

    The change in total IPSS score at 3 months as compared to baseline. The objective of the International Prostate Symptom Score (IPSS) is to capture the severity of urinary symptoms related to benign prostatic hyperplasia IPSS ranges from 0 to 35. A higher score indicates a worse outcome.

    Time frame: 3 months post-treatment

07

Results

Posted Jun 28, 2023
Limitations and caveats
The main limitation is that the trial is a single-arm study with a pre-specified performance goal and not randomized against another treatment arm.

Participant flow

Treatment
Participant flow — Treatment
MilestoneAquablation Procedure
Started101
Completed101
Not completed0
1 Month Follow-Up
Participant flow — 1 Month Follow-Up
MilestoneAquablation Procedure
Started101
Completed101
Not completed0
3 Months Follow-Up
Participant flow — 3 Months Follow-Up
MilestoneAquablation Procedure
Started99
Completed99
Not completed0
6 Months Follow-Up
Participant flow — 6 Months Follow-Up
MilestoneAquablation Procedure
Started100
Completed100
Not completed0
12 Months Follow-Up
Participant flow — 12 Months Follow-Up
MilestoneAquablation Procedure
Started96
Completed96
Not completed0
24 Months Follow-Up
Participant flow — 24 Months Follow-Up
MilestoneAquablation Procedure
Started86
Completed86
Not completed0
36 Months Follow-Up
Participant flow — 36 Months Follow-Up
MilestoneAquablation Procedure
Started82
Completed82
Not completed0
48 Months Follow-Up
Participant flow — 48 Months Follow-Up
MilestoneAquablation Procedure
Started66
Completed66
Not completed0
60 Months Follow Up
Participant flow — 60 Months Follow Up
MilestoneAquablation Procedure
Started62
Completed60
Not completed2
Withdrew: Withdrawal by subject2

Outcome measures

PrimaryIncidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment

The percentage of subjects with adverse events rated as probably or definitely related to the study procedure classified as Clavien-Dindo Grade 2 or higher or any Grade 1 event resulting in persistent disability (e.g. ejaculatory disorder or erectile dysfunction) evidenced through 3 months post treatment.

Time frame:
3 months post-treatment
Reported as:
Number · percentage
Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment
percentageAquablation Procedure
Incidence of Clavien-Dindo Adverse Events (Percentage of Participants) Through 3 Months Post Treatment45.5
PrimaryChange in Total International Prostate Symptom Score (IPSS) Score at 3 Months as Compared to Baseline

The change in total IPSS score at 3 months as compared to baseline. The objective of the International Prostate Symptom Score (IPSS) is to capture the severity of urinary symptoms related to benign prostatic hyperplasia IPSS ranges from 0 to 35. A higher score indicates a worse outcome.

Time frame:
3 months post-treatment
Reported as:
Mean · score on a scale
Change in Total International Prostate Symptom Score (IPSS) Score at 3 Months as Compared to Baseline
score on a scaleAquablation Procedure
Change in Total International Prostate Symptom Score (IPSS) Score at 3 Months as Compared to Baseline-16.5 (-18.1 to -14.8)
Post-hocChange in Total International Prostate Symptom Score (IPSS) Score at 60 Months as Compared to Baseline

The change in total IPSS score at 60 months as compared to baseline The objective of the International Prostate Symptom Score (IPSS) is to capture the severity of urinary symptoms related to benign prostatic hyperplasia IPSS ranges from 0 to 35. A higher score indicates a worse outcome.

Time frame:
60 months post-treatment

Results for this outcome have not been posted.

Adverse events

Collected over 2 years. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Aquablation Procedure0/101 (0%)18/101 (17.8%)82/101 (81.2%)
Most frequent serious events
Most frequent serious events
EventAquablation Procedure
BleedingSurgical and medical procedures9/101
CardiacCardiac disorders3/101
OtherGeneral disorders3/101
Scrotal edemaReproductive system and breast disorders2/101
Cerebrovascular accidentNervous system disorders1/101
Multi-system organ failureGeneral disorders1/101
Urinary incontinenceRenal and urinary disorders1/101
Urinary retentionRenal and urinary disorders1/101
Most frequent other events
Most frequent other events
EventAquablation Procedure
Ejaculatory dysfunctionReproductive system and breast disorders23/101
Urinary incontinenceRenal and urinary disorders16/101
OtherGeneral disorders14/101
DysuriaRenal and urinary disorders12/101
Urinary tract infectionInfections and infestations12/101
BleedingSurgical and medical procedures8/101
PainGeneral disorders6/101

Baseline characteristics

Age, Continuous
Age, Continuous(years)Aquablation Procedure
Mean67.5 ± 6.6
Sex: Female, Male
Sex: Female, Male(Participants)Aquablation Procedure
Female0
Male101
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Aquablation Procedure
Hispanic or Latino9
Not Hispanic or Latino92
Unknown or Not Reported0
Race/Ethnicity, Customized
Race/Ethnicity, Customized(Participants)Aquablation Procedure
Race — Asian5
Race — Black6
Race — White88
Race — Other2
Region of Enrollment
Region of Enrollment(participants)Aquablation Procedure
Canada19
United States82
Body mass index
Body mass index(kg/m^2)Aquablation Procedure
Mean28.4 ± 4.2
Prostate size (TRUS)
Prostate size (TRUS)(cc)Aquablation Procedure
Mean107.4 ± 22.1
International Prostate Symptom Score (IPSS)
International Prostate Symptom Score (IPSS)(score on a scale)Aquablation Procedure
Mean23.2 ± 6.3
08

Study locations

16 sites
  • Mayo Clinic Arizona
    Phoenix, Arizona 85054, United States
  • Tibor Rubin VA Medical Center
    Long Beach, California 90822, United States
  • University of Southern California, Institute of Urology
    Los Angeles, California 90089, United States
  • San Diego Clinical Trials
    San Diego, California 92120, United States
  • Indiana University School of Medicine
    Indianapolis, Indiana 46202, United States
  • Adult & Pediatrics Urology
    Omaha, Nebraska 68114, United States
  • Albany Medical College
    Albany, New York 12208, United States
  • Icahn School of Medicine at Mount Sinai
    New York, New York 10029, United States
  • Wake Forest School of Medicine
    Winston-Salem, North Carolina 27157, United States
  • UT Southwestern Medical Center
    Dallas, Texas 75390-9110, United States
  • University of Vermont
    Burlington, Vermont 05054, United States
  • Virginia Urology
    Richmond, Virginia 23235, United States
  • Urology of Virginia
    Virginia Beach, Virginia 23462, United States
  • University of British Columbia
    Vancouver, British Columbia V5Z 1M9, Canada
  • University of Toronto-University Health Network
    Toronto, Ontario M5G 1Z6, Canada
  • Université de Montréal
    Montréal, Quebec H2X 0A9, Canada
09

References and documents

Publications

  • Bhojani N, Bidair M, Kramolowsky E, Desai M, Doumanian L, Zorn KC, Elterman D, Kaufman RP Jr, Eure G, Badlani G, Plante M, Uchio E, Gin G, Paterson R, So A, Roehrborn C, Motola J, Kaplan S, Humphreys M. Aquablation Therapy in Large Prostates (80-150 mL) for Lower Urinary Tract Symptoms Due to Benign Prostatic Hyperplasia: Final WATER II 5-Year Clinical Trial Results. J Urol. 2023 Jul;210(1):143-153. doi: 10.1097/JU.0000000000003483. Epub 2023 Apr 28. PubMed 37115632 ↗
  • Desai M, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP Jr, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Roehrborn C, Kaplan S, Motola J, Bhojani N. Aquablation for benign prostatic hyperplasia in large prostates (80-150 mL): 6-month results from the WATER II trial. BJU Int. 2019 Aug;124(2):321-328. doi: 10.1111/bju.14703. Epub 2019 Mar 29. PubMed 30734990 ↗
  • Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP Jr, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys MR, Roehrborn CG, Kaplan S, Motola J, Zorn KC. Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results. Can J Urol. 2020 Apr;27(2):10147-10153. PubMed 32333733 ↗
  • Desai M, Bidair M, Bhojani N, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP Jr, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Roehrborn C, Kaplan S, Motola J, Zorn KC. WATER II (80-150 mL) procedural outcomes. BJU Int. 2019 Jan;123(1):106-112. doi: 10.1111/bju.14360. Epub 2018 Jun 10. PubMed 29694702 ↗
  • Bhojani N, Bidair M, Zorn KC, Trainer A, Arther A, Kramolowsky E, Doumanian L, Elterman D, Kaufman RP, Lingeman J, Krambeck A, Eure G, Badlani G, Plante M, Uchio E, Gin G, Goldenberg L, Paterson R, So A, Humphreys M, Kaplan S, Motola J, Desai M, Roehrborn C. Aquablation for Benign Prostatic Hyperplasia in Large Prostates (80-150 cc): 1-Year Results. Urology. 2019 Jul;129:1-7. doi: 10.1016/j.urology.2019.04.029. Epub 2019 May 3. PubMed 31059728 ↗
  • Chughtai B, Thomas D. Pooled Aquablation Results for American Men with Lower Urinary Tract Symptoms due to Benign Prostatic Hyperplasia in Large Prostates (60-150 cc). Adv Ther. 2018 Jun;35(6):832-838. doi: 10.1007/s12325-018-0722-0. Epub 2018 Jun 5. PubMed 29873008 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: Undecided

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Aug 2017 to primary completion in Mar 2018, 7 months.

Results were first posted in Jun 2023, 5 years 3 months after primary completion.

Of 52 industry-sponsored interventional studies with no phase under Prostatic Hyperplasia, half reached primary completion within 30 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 50. This study's 7 months is below that.

Counting every sponsor, half of 207 studies reached it within 27 months; a quarter within 15 and three quarters within 48.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 11, 2017
First posted
Apr 21, 2017
StartActual
Aug 14, 2017
Primary completionActual
Mar 27, 2018
CompletionActual
Dec 20, 2022
Results first posted
Jun 28, 2023
Last update
Jun 28, 2023
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jun 28, 2023, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03123250
Lead sponsor
PROCEPT BioRobotics
Responsible party
Sponsor
First posted
Apr 21, 2017
Start date
Aug 14, 2017
Primary completion
Mar 27, 2018
Completion
Dec 20, 2022
Results posted
Jun 28, 2023
Last update
Jun 28, 2023

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jun 2023. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion